Center for Technology Commercialization

  • Featured Technology


    Lung Cancer Therapeutic

  • Show All

    Technology Overview

    Midkine (MDK) activates the PI3K pathway and induces anti-apoptotic activity, in turn enhancing the survival of tumors.

    Therefore, the inhibition of MDK is considered a potential strategy for cancer therapy. We have identified a novel small molecule compound (iMDK) that targets MDK. iMDK inhibited the cell growth of H441 lung adenocarcinoma cells that harbor an oncogenic KRAS mutation and H520 squamous cell lung cancer cells, but did not affect the growth of MDK-negative adenocarcinoma cells or normal lung cells. Inhibition of MDK with iMDK provides a potential therapeutic approach for the treatment of lung cancers that are driven by MDK.

    Applications

    • Small molecule therapeutic for the treatment of currently untreatable lung cancers.

    Advantages

    • Selectivity
    • Specificity

    Market Overview

    For an in-depth market overview, please click here.

    • Lung cancer is the leading cancer killer among men and women and was responsible for the deaths of an estimated 160,000 Americans in 2012. 
    • Approximately 375,000 Americans are living with lung cancer and an estimated 226,000 new cases were diagnosed in 2012.

    Patent Information

    PCT Pending
    PCT/US2014/043029
    Priority Date: 06/20/2013

    Lead Investigator

    Publication


  • For more information, please contact CTC Business Development at partnering@cchmc.org or 513-636-4285.
 
  • Previously Featured Technologies

    Learn more about our previously featured technologies.